Early-stage medical device company Freyja Healthcare has received 510(k) clearance from the US Food and Drug Administration (FDA) for its VereSee device, used in laparoscopic surgery. 

Laparoscopic surgery is a minimally invasive surgical technique where small incisions are made in the abdomen, through which specialised instruments and a tiny camera are inserted. The camera allows surgeons to view the inside of the body on a monitor, guiding them as they perform the procedure. 

The VereSee device is a 2mm abdominal-access video-entry device designed for laparoscopic surgery in women’s health. The availability of the device for commercial use is projected for the second half of 2024.  

“The standard of care is dangerous and outdated,” said Freyja’s interim CEO Jón Ívar Einarsson.

“Initial entry is often done blindly with Veres needles or a 5mm-12mm optical trocar. Damaging the bowel or vasculature because of blind entry can cause significant harm, even death, if undetected.” 

Founded in 2017, Freyja has raised almost $8m in seed funding, raising $1m in a Series A funding round in April 2019. VereSee is the Boston-based company’s lead device, with four products in advanced stages of development. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to GlobalData analysis, the overall laparoscopic access instruments market will generate $299m in 2030. The market is expected to grow, due to the rise in the number of surgical and minimally invasive procedures.  

Innovation in the laparoscopic space includes the development of robotic and magnetic surgery platforms. In August 2023, the FDA granted clearance to Levita Magnetics’ MARS magnetic surgery platform, where a magnet and machine combine to give surgeons tissue manipulation control with fewer scars in laparoscopic procedures. 

In July 2023, researchers from École polytechnique fédérale de Lausanne (EPFL) in Switzerland developed a four-arm laparoscopic system. It features shared control between a surgeon and robotic assistants, with each hand operating a manipulative instrument while one foot operates an endoscope, and the other foot operates an actuated gripper. The robotic system aims to reduce surgeon workload and enhance the precision and safety of surgeries.